Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60–70% of patients remain progression-free after 5 years. Given a median age of 65, it is relevant to disentangle how DLBCL and DLBCL therapy influence health care...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobsen, Lasse Hjort, Øvlisen, Andreas Kiesbye, Severinsen, Marianne Tang, Bæch, Joachim, Kragholm, Kristian Hay, Glimelius, Ingrid, Gang, Anne Ortved, Jørgensen, Judit Mészáros, Frederiksen, Henrik, Poulsen, Christian Bjørn, Clausen, Michael Roost, Pedersen, Per Trøllund, Pedersen, Robert Schou, Torp-Pedersen, Christian, Eloranta, Sandra, El-Galaly, Tarec Christoffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795387/
https://www.ncbi.nlm.nih.gov/pubmed/35087026
http://dx.doi.org/10.1038/s41408-022-00614-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795387/
https://www.ncbi.nlm.nih.gov/pubmed/35087026
http://dx.doi.org/10.1038/s41408-022-00614-8

Ejemplares similares